Regorafenib (Dingpai) 40mg*28's | Zhejiang Huayi China | GLT

Generic Information: Dingpai (China)

Dingpai (鼎派) is a Chinese-market brand of regorafenib manufactured by Zhejiang Huayi Pharmaceutical Co., Ltd., a domestic manufacturer of oncology and specialty medicines. This pack holds 28 film-coated tablets, each containing 40 mg of regorafenib. Dingpai offers a licensed, accessible alternative to the Bayer originator Stivarga for patients requiring later-line multi-kinase inhibition.

What Is Regorafenib (Dingpai) Used For?

Dingpai is used for three advanced cancers. It treats metastatic colorectal cancer that has progressed despite fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy plus anti-VEGF and, where appropriate, anti-EGFR therapy. It is also indicated for gastrointestinal stromal tumour resistant to imatinib and sunitinib, and for hepatocellular carcinoma that has progressed on sorafenib. In all cases it is a later-line therapy for disease control.

How Does Regorafenib Work?

Regorafenib is an oral inhibitor of multiple kinases that drive tumour growth and angiogenesis. Its targets include the VEGF receptors 1, 2 and 3, TIE2, PDGFR-α and β, FGFR-1 and 2, KIT, RET, RAF-1 and BRAF. This broad inhibition suppresses cancer-cell proliferation and the formation of tumour blood vessels at the same time, which is why the drug is effective across colorectal, stromal-tumour and liver cancers.

Indications

The approved indications are advanced colorectal cancer after standard chemotherapy, imatinib- and sunitinib-resistant gastrointestinal stromal tumour, and sorafenib-refractory hepatocellular carcinoma. Treatment should be initiated and monitored by an oncologist, with liver function and blood pressure assessed before and during therapy.

Dosage

The recommended dose is 160 mg (four 40 mg tablets) once daily with a low-fat meal, given in 28-day cycles of 21 days on and 7 days off. A 28-tablet pack supplies seven days of the active-treatment phase. The dose may be reduced to 120 mg or 80 mg daily if side effects such as hand-foot skin reaction or liver enzyme elevations occur.

Side Effects

The most common side effects are hand-foot skin reaction, diarrhoea, fatigue, hypertension, decreased appetite and mouth inflammation. Serious but less frequent effects include liver injury, bleeding, gastrointestinal perforation and cardiac problems. Regular monitoring of liver function, blood pressure and blood counts is recommended, and patients should promptly report skin peeling, persistent diarrhoea, dark stools or chest pain.

Storage

Store Dingpai tablets at room temperature, protected from moisture, in the original package and out of the reach of children. Do not use beyond the expiry date printed on the pack.

Why Choose Dingpai Through GLT?

Dingpai gives overseas patients and institutions a dependable, lower-cost Chinese regorafenib from a licensed domestic manufacturer. GLT sources directly from established Chinese producers and ships worldwide from a Hong Kong-licensed facility, making later-line cancer therapy more affordable and accessible over the long term.

How to Order

To order Dingpai (regorafenib) from GLT, contact us on WhatsApp at +86 15234153837 or by email at [email protected]. We will confirm current availability, pricing and delivery to your country, and we ship from a Hong Kong-licensed facility.

FAQ

Is Dingpai the same as Stivarga? Yes — it contains the same regorafenib molecule, manufactured by Zhejiang Huayi as a licensed Chinese product.

What is the dosing schedule? 160 mg once daily for 21 days, then a 7-day break, repeated every 28 days.

Do I need a prescription? Yes, regorafenib is prescription-only and requires a valid oncologist's prescription.